December 20, 2004 The Santa Claus rally didn’t materialize among biotech stocks today as the Centient Biotech 200 moved lower by 12.5 points or .35%, to close at 3524.29. That almost exactly matched Nasdaq’s loss, while the NYSE Composite rose by .27%. We discuss Cambridge Antibody’s favorable verdict in a lawsuit, Genaissance’s genetic markers, EyeTech’s performance on the “day after,” Pharmos’s disaster, ViroPharma’s nearly 10% slip, and the continuing fallout surrounding Pfizer.
